Menu
← Oncology Approval Tracker
FDA DECISION ·
Aphexda + filgrastim
motixafortide + filgrastim · BioLineRx
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With filgrastim to mobilize blood-forming stem cells for collection and later autologous transplantation in patients with multiple myeloma.
LAMPGEN ANALYSIS
Why it matters
The approval adds a CXCR4-directed mobilization option before autologous transplant.
What research teams should watch
Coordinate dosing and premedication with the apheresis schedule and document collection yield.
PRIMARY RECORDS